The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

20131217_4

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS
ISSUE 46 – DEC. 13, 2013PDF

CPRIT Official Indicted for Skipping Peer ReviewBy Paul GoldbergA grand jury in Travis County, Texas, indicted a former official of the Cancer Prevention and Research Institute of Texas for bypassing peer review in awarding an $11 million grant to a Dallas-based company.
photoWhy I Don’t Want to Pay for Your Horoscope:Reflections on FDA Warning to 23andMeGuest Editorial by Jim EvansThere’s been much recent gnashing of teeth (at least within the narrow and rather insular world of do-it-yourself genomics) about the gall of the FDA in choosing to issue a warning letter to 23andMe, effectively shutting down marketing of their direct-to-consumer personal genomic profiling. And adding to 23andMe’s woes, a class action suit has been filed against them.
photoBipartisan Deal Eases Some Budget Cuts By Extending Sequestration Through 2023By Matthew Bin Han OngThe House of Representatives voted 332-94 to approve a two-year budget outline Dec. 12 that would cancel $63 billion in sequester cuts for 2014 and 2015—in exchange for extending sequestration through 2023.
photoIn Brief
  • Thomas Burke stepped down as executive vice president and physician-in-chief at MD Anderson Cancer Center
  • Edward Jackson named chair of the Department of Medical Physics at the University of Wisconsin School of Medicine and Public Health
  • David Chang appointed professor of plastic surgery at the University of Chicago School of Medicine
  • Steve Mackin named chief operating officer of Cancer Treatment Centers of America

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account